Ciprofloxacin 0.3% Thephaco Uses

sponsored
How old is patient?

What is Ciprofloxacin 0.3% Thephaco?

Ciprofloxacin 0.3% Thephaco is an antibiotic in a group of drugs called fluoroquinolones (flor-o-KWIN-o-lones). Ciprofloxacin 0.3% Thephaco fights bacteria in the body.

Ciprofloxacin 0.3% Thephaco is used to treat different types of bacterial infections. Ciprofloxacin 0.3% Thephaco is also used to treat people who have been exposed to anthrax.

Ciprofloxacin 0.3% Thephaco may also be used for purposes not listed in this medication guide.

Ciprofloxacin 0.3% Thephaco indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Ciprofloxacin 0.3% Thephaco tablets USP are indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below.

Urinary Tract Infections

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis.

Acute Uncomplicated Cystitis

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus.

Chronic Bacterial Prostatitis

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.

Lower Respiratory Tract Infections

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, Ciprofloxacin 0.3% Thephaco tablets USP are indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis.

Acute Sinusitis

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.

Skin and Skin Structure Infections

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.

Bone and Joint Infections

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.

Complicated Intra-Abdominal Infections

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.

Infectious Diarrhea

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii†,Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated.

†Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients.

Typhoid Fever (Enteric Fever)

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of Ciprofloxacin 0.3% Thephaco in the eradication of the chronic typhoid carrier state has not been demonstrated.

Uncomplicated Cervical and Urethral Gonorrhea

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae.

Complicated Urinary Tract Infections and Pyelonephritis

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli.

Inhalational Anthrax (post-exposure)

Ciprofloxacin 0.3% Thephaco tablets USP are indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Ciprofloxacin 0.3% Thephaco serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for Ciprofloxacin 0.3% Thephaco for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.

Plague

Ciprofloxacin 0.3% Thephaco tablets USP are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of Ciprofloxacin 0.3% Thephaco could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.

Limitation of Use

Use in Pediatric Patients

Although effective in clinical trials, Ciprofloxacin 0.3% Thephaco is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin 0.3% Thephaco tablets USP, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.

Lower Respiratory Tract Infections

Ciprofloxacin 0.3% Thephaco tablets USP are not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin 0.3% Thephaco tablets USP and other antibacterial drugs, Ciprofloxacin 0.3% Thephaco tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Ciprofloxacin 0.3% Thephaco. Therapy with Ciprofloxacin 0.3% Thephaco tablets USP may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Ciprofloxacin 0.3% Thephaco. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.

How should I use Ciprofloxacin 0.3% Thephaco?

Use Ciprofloxacin 0.3% Thephaco as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Ciprofloxacin 0.3% Thephaco comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Ciprofloxacin 0.3% Thephaco refilled.
  • An extra patient leaflet may be available with Ciprofloxacin 0.3% Thephaco. Talk to your pharmacist if you have questions about this information.
  • Take Ciprofloxacin 0.3% Thephaco by mouth with or without food. The preferred dosing time is 2 hours after a meal.
  • Shake well before each use.
  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
  • Take Ciprofloxacin 0.3% Thephaco with a full glass of water (8 oz [240 mL]).
  • Drinking extra fluids while you are taking Ciprofloxacin 0.3% Thephaco is recommended. Check with your doctor for instructions.
  • If you also take any products containing magnesium, aluminum, calcium, iron, or zinc (eg, antacids, quinapril, vitamins/minerals); didanosine; sucralfate; or bismuth subsalicylate, do not take them within 6 hours before or 2 hours after taking Ciprofloxacin 0.3% Thephaco. Check with your doctor if you have questions.
  • If you also take sevelamer, do not take it within 4 hours before or after taking Ciprofloxacin 0.3% Thephaco. Check with your doctor if you have questions.
  • Ciprofloxacin 0.3% Thephaco works best if it is taken at the same time each day.
  • To clear up your infection completely, take Ciprofloxacin 0.3% Thephaco for the full course of treatment. Keep taking it even if you feel better in a few days.
  • Avoid taking Ciprofloxacin 0.3% Thephaco with milk or milk products (eg, calcium-enriched juice, yogurt) by themselves. However, taking Ciprofloxacin 0.3% Thephaco as part of a full meal that contains milk or milk products is permitted.
  • Do not miss any doses. If you miss a dose of Ciprofloxacin 0.3% Thephaco, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ciprofloxacin 0.3% Thephaco.

Uses of Ciprofloxacin 0.3% Thephaco in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Ciprofloxacin 0.3% Thephaco is used to treat wide range of bacterial infections including lung or respiratory tract infections, eye infection, bladder and kidney infections, reproductive tract infections, skin and soft tissue infections and bone and joint infections.

Ciprofloxacin 0.3% Thephaco description

infoPharmacology is a crucial part of medicine wherein various medications are used to advance the well-being of an individual. Some drugs cure the infection or a disease; few prevent the occurrence of a symptom or a disease, and few are used in long-term treatment of the disease. Drugs are obtained from the plants as well as they can be synthesized organically. The drugs are used in various combinations or a single drug by the pharmaceutical industry during its preparation. The half-life of each medicine is different, and the dosage of the drug depends on the half-life of the drug.

Ciprofloxacin 0.3% Thephaco is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein synthesis.

Ciprofloxacin 0.3% Thephaco is marketed worldwide with over three hundred different brand names. In the United States, Canada and the UK, it is marketed as Ciloxan, Cipro, Cipro XR, Cipro XL Ciproxin and, most recently, Proquin. In Mexico it is available over the counter and marketed under the names Ciproflox or Ciprofloxacino. In Ecuador it is available and marketed under the name Cidrax. In Nigeria it is sold as Ciprotab while in Bangladesh it is marketed as Tablets and Microcapsules for Suspension by numerous companies, one of which is by Edruc Limited as Cipron. Additionally, Ciprofloxacin 0.3% Thephaco is available as a generic drug under a variety of different brand names and is also available for limited use in veterinary medicine.

Ciprofloxacin 0.3% Thephaco was first patented in 1983 by Bayer A.G. and subsequently approved by the United States Food and Drug Administration (FDA) in 1987.Ciprofloxacin 0.3% Thephaco has 12 F.D.A.-approved human uses and other veterinary uses, but it is often used for non-approved uses (off-label).

Ciprofloxacin 0.3% Thephaco interacts with other drugs, herbal and natural supplements, and thyroid medications.


sponsored

Active ingredient matches for Ciprofloxacin 0.3% Thephaco:

Ciprofloxacin in Vietnam.


Unit description / dosage (Manufacturer)Price, USD
Ciprofloxacin 0.3% Thephaco 0.3 % x 1 Bottle x 10 mL

List of Ciprofloxacin 0.3% Thephaco substitutes (brand and generic names):

References

  1. DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
  2. Wikipedia. "ciprofloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Ciprofloxa... (accessed September 18, 2017).
  3. PubChem. "ciprofloxacin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
  4. FDA Orange Book. "CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).

Reviews

The results of a survey conducted on ndrugs.com for Ciprofloxacin 0.3% Thephaco are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ciprofloxacin 0.3% Thephaco. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 22 here

 
| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2017 ndrugs.com All Rights Reserved